| 2215-CL-0301 | A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation | Leber, Dr Brian | Open | NCT02421939 |
| INSPIRE | A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent | Leber, Dr Brian | Open | NCT02562443 |
| M15-656 | A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy | Leber, Dr Brian | Open | NCT02993523 |
| MCRN 004 | A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma. | Kouroukis, Dr Tom | Open | NCT03215524 |
| SGI-110-07 | A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents | Leber, Dr Brian | Open | NCT02907359 |
| M15-550 | Open-label, single arm, phase 3b, multi-center study evaluating the efficacy of Venetoclax (ABT-199) in relapsed/refractory subjects with chronic lymphocytic leukemia (CLL) including those with the 17p deletion or TP53 mutation OR those who are refractory or intolerant to B-cell receptor inhibitors | Leber, Dr Brian | Open | NCT02756611 |
| LY.17 | A MULTI-STAGE RANDOMIZED PHASE II STUDY OF NOVEL COMBINATION THERAPY IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE B-CELL LYMPHOMA | Fraser, Dr Graeme | On hold | NCT02436707 |
| CINC424C2301 (REACH 2) | A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation | Leber, Dr Brian | On hold | NCT02953678 |
| CINC424D2301 (REACH 3) | A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH 3) | Foley, Dr Ronan | On hold | NCT03112603 |
| AZA-MDS-003 | A phase 3, multicentre, randomized, double-blind study to compare with efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusion-dependent anemia and thrombocytopenia due to IPSS lower-risk myelodysplatic syndromes | Leber, Dr Brian | On hold | NCT01566695 |
Find a Trial
Contact Us